Avraham Pharmaceuticals

Company Overview

Snapshot

Founded in February 2010 by Michael Horev, Marta Weinstock-Rosin, and Moussa B.H. Youdim, Avraham Pharmaceuticals operates with 1–10 employees. The company has secured $26.2 million across 5 funding rounds from 5 investors. In February 2016, the company closed an additional investment round, reinforcing its development efforts.

Business overview

Avraham Pharmaceuticals is a pharmaceutical company focused on developing novel products for the treatment and prevention of neurodegenerative disorders, including Alzheimer's disease, Lewy body disease, and Parkinson's disease. The company's core product candidate, Ladostigil, is exclusively in-licensed from the Hebrew University and the Technion and is currently in phase 2 clinical studies for mild cognitive impairment (MCI). Ladostigil is a multifunctional compound designed to combine neuro-protective mechanisms, reduce oxidative stress and microglial activation, and inhibit pro-inflammatory cytokines, with the potential to slow the progression of Alzheimer's disease in MCI patients. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In July 2014, Avraham Pharmaceuticals reported positive. This milestone is significant as it provides clinical validation for the drug's efficacy in addressing a critical stage of neurodegenerative disorders, suggesting potential for slowing the progression of Alzheimer's disease. For investors, this indicates a positive advancement in the company's clinical development pipeline and de-risks future stages of drug development.

Company Intelligence Q&A

What is Avraham Pharmaceuticals' primary focus?

Avraham Pharmaceuticals is focused on developing novel products for the treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, and Parkinson's disease.

What is Ladostigil?

Ladostigil is Avraham Pharmaceuticals' lead product candidate, exclusively in-licensed from the Hebrew University and the Technion. It is a multifunctional compound in phase 2 clinical studies for mild cognitive impairment (MCI), designed to combine neuro-protective mechanisms, reduce oxidative stress, and inhibit pro-inflammatory cytokines.

When did Avraham Pharmaceuticals report positive Phase IIb results for Ladostigil?

In July 2014, Avraham Pharmaceuticals reported positive Phase IIb results for Ladostigil in the treatment of mild cognitive impairment (MCI).

Which investors participated in Avraham Pharmaceuticals' February 2016 funding round?

In February 2016, Avraham Pharmaceuticals received investment from Clal Biotechnology Industries (CBI) and Integra Holdings.

When was Avraham Pharmaceuticals founded and by whom?

Avraham Pharmaceuticals was founded in February 2010 by Michael Horev, Marta Weinstock-Rosin, and Moussa B.H. Youdim.